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Abstract  40 
STUDY QUESTION: What are the key core outcomes to be reported in studies on 41 
polycystic ovary syndrome (PCOS)? 42 
SUMMARY ANSWER: We identified three generic and 30 specific core outcomes in six 43 
domains (AUTHOR: the main text and Fig. 1 state seven domains. Please would you recheck 44 
or clarify?): metabolic (eight), reproductive (7) (AUTHOR: correct, as below?), pregnancy 45 
(10), oncological (one), psychological (one), and long-term outcomes (one).  46 
WHAT IS KNOWN ALREADY: Research reporting PCOS is heterogeneous with high 47 
variation in outcome selection, definition and quality. 48 
STUDY DESIGN, SIZE, DURATION: Evidence synthesis and a modified Delphi method 49 
with e-surveys were used as well as a consultation meeting. 50 
PARTICIPANTS/MATERIALS, SETTING, METHODS: Overall, 71 health 51 
professionals and 123 lay consumers (women with lived experience of PCOS and members 52 
of advocacy and peer support groups) (AUTHOR: it may be helpful for the reader to briefly 53 
describe who was included the lay consumer group. Thank you.)  from 17 high-, middle- and 54 
low-income countries were involved in this analysis. 55 
MAIN RESULTS AND THE ROLE OF CHANCE: The final core outcome set included 56 
three generic outcomes (BMI, quality of life, treatment satisfaction) that are applicable to all 57 
studies on women with PCOS and 30 specific outcomes that were categorised into six 58 
domains (AUTHOR: the main text and Fig. 1 state seven domains. Please would you recheck 59 
or clarify?): eight metabolic outcomes (waist circumference, type 2 diabetes, insulin 60 
resistance, impaired glucose tolerance, hypertension, coronary heart disease, lipids profile, 61 
venous thromboembolic disease); seven reproductive outcomes [viable pregnancy (confirmed 62 
by ultrasound including singleton, twins, and higher multiples), clinical and biochemical 63 
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hyperandrogenism, menstrual regularity, reproductive hormonal profile, chronic anovulation, 64 
ovulation stimulation success including the number of stimulated follicles≥12mm, incidence 65 
and severity of ovarian hyperstimulation syndrome]; 10 pregnancy outcomes (live birth, 66 
miscarriage, stillbirth, neonatal mortality, gestational weight gain, gestational diabetes, pre-67 
term birth, hypertensive disease in pregnancy, baby birth weight, major congenital 68 
abnormalities); three psychological outcomes (depression, anxiety, eating disorders); one 69 
oncological (abnormal endometrial proliferation including atypical endometrial hyperplasia 70 
and endometrial cancer); and one outcome in the long-term domain (long-term offspring 71 
metabolic and developmental outcomes). 72 
LIMITATIONS, REASONS FOR CAUTION: We involved lay consumers in all stages of 73 
study through e-surveys but not through focus groups, thereby limiting our understanding of 74 
their choices. We did not address the variations in the definitions and measurement tools for 75 
some of the core outcomes.  76 
WIDER IMPLICATIONS OF THE FINDINGS: Implementing this core outcome set in 77 
future studies on women with PCOS will improve the quality of reporting and aid evidence 78 
synthesis. 79 
STUDY FUNDING/COMPETING INTEREST(S): Evidence synthesis was funded 80 
through the Australian government, National Health and Medical Research Council 81 
(NHMRC) Centre for Research Excellence in PCOS and HT is funded through an NHMRC 82 
fellowship. BHA is funded through an NIHR lectureship. All authors have no competing 83 
interest to declare. 84 




Polycystic ovary syndrome (PCOS) is the commonest chronic endocrine condition, affecting 88 
8-13% of women of reproductive age (Bozdag et al., 2016). With a variety of metabolic, 89 
reproductive and psychological features, PCOS predisposes women to adverse health 90 
outcomes such as diabetes, metabolic syndrome, depression and subfertility (Azziz et al., 91 
2016; Teede et al., 2010). Care for women with PCOS remains fragmented across various 92 
health professionals, including primary care physicians, gynaecologists, endocrinologists, 93 
fertility specialists, specialist nurses, dieticians and allied health professionals, often leading 94 
to delayed diagnosis and inconsistent clinical management internationally (Teede et al., 95 
2010). This problem permeates into clinical research on PCOS with poor collaboration across 96 
health disciplines and inadequate prioritisation of key clinical outcomes as well as scarce 97 
engagement of lay consumers (Tay, Moran, et al., 2018). Selective and heterogeneous 98 
outcome reporting is common practice, often hindering meaningful evidence synthesis, 99 
increasing research wastage and limiting impact (Khan and O’Donovan, 2014). 100 
Consequently, the translation and implementation of evidence in clinical guidelines on PCOS 101 
remains limited despite an increasing number of clinical trials (Tay, Joham, et al., 2018). 102 
 103 
The use of condition-specific standardised sets of core outcomes as a minimum for reporting 104 
across future studies is recommended, to minimise variations in outcome reporting 105 
(Williamson et al., 2012). Several core outcomes sets have been successfully developed in an 106 
attempt to standardise reporting and improve research quality (Tugwell et al., 2007). We aim 107 
to identify those core outcomes to be minimally reported in clinical studies on PCOS using a 108 
modified Delphi method involving an international panel of stakeholders.    109 
 110 
Materials and Methods 111 
 6 
We developed a core outcome set for PCOS research using a prospectively registered 112 
protocol available online (Wattar et al., 2018) and reported our findings in line with current 113 
recommendations (Kirkham et al., 2016). The study had a dedicated Core Management 114 
Group (CMG) responsible for the study design and overall conduct (BHA, HT, RG, and ST) 115 
with oversight from the Guideline Development Group (GDG) of the 2018 international 116 
evidence-based guideline on the diagnosis and management of PCOS (Teede et al., 2018). 117 
Members of both groups took part in the survey anonymously. 118 
 119 
Identification of outcomes  120 
We identified a longlist of all relevant outcomes reported in clinical trials on PCOS using 40 121 
systematic reviews conducted by the GDG during the development of the international 122 
guideline (Teede et al., 2018). We initially categorised outcomes on this longlist into four 123 
main domains: metabolic, reproductive, pregnancy and long-term outcomes. To facilitate the 124 
Delphi voting process, we combined outcomes of similar clinical and physiological 125 
background under one label e.g. High-Density Lipoprotein, Low-Density Lipoprotein, and 126 
Triglycerides were combined under lipids profile. The final longlist was piloted among the 127 
CMG members before the start of the Delphi process for its face validity and ease of use; any 128 
disagreement was resolved by consensus. We generated lay definitions for all outcomes on 129 
the longlist using the University of Michigan simplification guide to medical terms to 130 
facilitate the participation of lay consumers in the Delphi process (University of Michigan, 131 
n.d.).  132 
 133 
Health professionals 134 
We included representatives of each of the following health professional stakeholder groups: 135 
endocrinologists, general obstetricians and gynaecologists, fertility specialists, academics, 136 
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specialist nurses and midwives, primary care physicians, and allied health specialists. We 137 
created a list of candidates per stakeholder group using the contacts of the CMG and the 138 
GDG members and leveraged the wider membership of the Androgen Excess and Polycystic 139 
ovary syndrome society (AE-PCOS) to expand our pool of international stakeholders 140 
(Androgen Excess and PCOS Society, n.d.). We sought stakeholder representation from 141 
specific countries to ensure a balanced representation of both developed and developing 142 
countries from all five continents.  143 
 144 
Modified Delphi method 145 
We asked health professionals to complete a two-round Delphi process using a custom-146 
designed electronic survey on Google Forms. In each round, participants were asked to score 147 
each of the outcomes on the longlist using a ten-point Likert scale anchored between zero 148 
(labelled ‘not important’) and 10 (labelled ‘very important’). Participants were able to 149 
suggest any additional outcomes at the end of the 1st Delphi round; all outcomes identified 150 
were incorporated and voted on in the 2nd Delphi round.  151 
 152 
At the end of the 1st round, we provided participants with individualised feedback comprising 153 
their individual score, the mean score of the whole group of health professionals, and the 154 
mean score of the lay consumers’ group for each outcome. Feedback was provided using 155 
individualised emails with an embedded custom-designed Google form prompting 156 
participants to consult those scores before providing their new scores for the 2nd round. The 157 
feedback design was aimed to promote reflection and reach consensus among participants by 158 
the end of the 2nd Delphi round. Non-responders received three reminders with a personalised 159 
message before being excluded from the 2nd round.  160 
 161 
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We used the following pre-specified consensus criteria: outcomes were included (core) if 162 
they had a score of ≥7 by more than 70% of participants and a score of ≤4 by less than 15% 163 
of participants. Outcomes were excluded (not core) if they received a score of ≥7 by less than 164 
15% of participants and a score of ≤4 by more than 70% of participants. Outcomes with any 165 
other score combinations were considered equivocal and were discussed at the final 166 
consultation meeting. Both rounds were moderated by the same researchers (BHA and RG). 167 
 168 
Patient and public involvement  169 
We sought input from a lay consumers group on both the study design and the Delphi 170 
process. Participants in the lay group were identified as women with lived experience of 171 
PCOS with an established diagnosis, or if they cared for their family members such as 172 
partners, or individuals with PCOS life-experiences such as leaders of advocacy and peer 173 
support groups. We leveraged links to established charities and lay support groups including 174 
Verity-PCOS UK and PCOS Challenge to engage their membership and promote 175 
participation in our study. Candidates were sent electronic invitations via emails and social 176 
media platforms, which included a brief summary of the study objectives, the consensus 177 
convergence process and the lay definitions of included outcomes. Participants were asked to 178 
score each of the outcomes on the longlist using a 10 points Likert scale anchored between 179 
zero (labelled ‘not important’) and 10 (labelled ‘very important’). They were also asked to 180 
provide any additional outcomes of relevance to women with PCOS.   181 
 182 
Consultation meeting  183 
We held a final consultation meeting involving the CMG and representatives from both the 184 
health professionals and lay consumers stakeholder groups. The meeting consisted of group 185 
discussions followed by two voting rounds using the same criteria to reach consensus. The 186 
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objectives of the meeting were to discuss all equivocal outcomes that did not reach consensus 187 
in the Delphi process, to agree and finalise the core outcomes list, and to devise a 188 
dissemination and implementation plan of the final core outcome set.  189 
 190 
Data analysis 191 
We collected data and Delphi scores using live online password-protected Google forms. 192 
Each participant was issued a unique identifier to avoid duplicate entries in the Delphi 193 
process. We collected basic demographics on the participants to ensure adequate 194 
representations across countries and disciplines. We reported using ranking orders, 195 
percentages and natural frequencies. All statistical analyses were conducted using Microsoft 196 
Excel 2013 (Microsoft Corp., Redmond, WA, USA). 197 
 198 
Results 199 
Participants and longlist of outcomes 200 
In total, 71 health professionals (16 endocrinologists, 14 fertility specialists, two general 201 
obstetricians and gynaecologists, 21 academics active in PCOS research, five paediatricians, 202 
five specialist nurses and midwives, two primary care physicians, one occupational therapist, 203 
one psychologist, one pharmacist, and three dieticians) and 123 lay consumers from 17 204 
countries (Australia, Belgium, Canada, Chile, China, Czech Republic, Estonia, France, India, 205 
Italy, Netherlands, South Africa, Spain, Sri Lanka, Sweden, UK, and USA) participated in the 206 
Delphi process. (Fig. 1) In the 2nd Delphi round, we received responses from 52 health 207 
professionals achieving a 74% response rate.  208 
 209 
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Initially, 60 outcomes were included in the longlist: 16 metabolic, 17 reproductive, 16 210 
pregnancy, and 11 long-term outcomes. (Table I) Five additional outcomes were suggested 211 
by participants at the end of the 1st round and were included in the 2nd round; two outcomes 212 
by lay consumers (body image and treatment satisfaction) and three outcomes by health 213 
professionals (skin disorders, hepatic and visceral fat, adiponectin levels). At the time of 214 
conception of this longlist, we received the findings of the COMMIT core outcome set which 215 
identified all core outcomes for reporting on infertility treatment in women’s health (Duffy 216 
and Farquhar, 2017). We included the following outcomes in our longlist and Delphi process 217 
to seek stakeholders’ input on their relevance to PCOS research: viable pregnancy confirmed 218 
by ultrasound including singleton pregnancy, twin pregnancy, and higher multiples; 219 
pregnancy loss including miscarriage and stillbirth; live birth; gestational age at delivery; 220 
birthweight; neonatal mortality; and major congenital abnormalities (AUTHOR: please 221 
would you check that the punctuation is correct for this list? Thank you.). Three outcomes 222 
were judged as not particularly relevant to PCOS by the CMG and were not included in the 223 
Delphi process: termination of pregnancy, ectopic pregnancy, and time to pregnancy leading 224 
to live birth.  225 
 226 
Delphi survey 227 
After the 2nd round of the Delphi process, 40 out of 65 outcomes (62%) were identified as 228 
important for inclusion in the final core outcome set (Table I). Seven outcomes (7/65, 11%) 229 
were considered to be of low importance (endometriosis, adnexal adhesions, sexually 230 
transmitted disease, nipple discharge, induction of labour, cervical cancer, and ovarian 231 
cancer). All remaining outcomes (18/65, 28%) were equivocal with no clear consensus. 232 
 233 
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There was clear consensus for twenty-nine outcomes being considered important by both 234 
health professionals and lay consumers through all stages of the Delphi. (Table I) Eleven 235 
outcomes were identified as important by lay consumers but were not prioritised by health 236 
professionals by the end of the 2nd Delphi round (markers of cardiovascular disease, 237 
cerebrovascular disease, dysmenorrhea, thyroid function tests, major congenital 238 
abnormalities, endometriosis, adnexal adhesions, breast cancer, cervical cancer, ovarian 239 
cancer, and ovarian cysts). In contrast, three outcomes were considered to be important by 240 
health professionals but not by lay consumers (waist circumference, ovarian hyperstimulation 241 
syndrome, and baby birthweight).     242 
 243 
Lay consumers’ input led to a significant shift in health professionals’ opinion, prioritising 244 
four outcomes as important by the end of the second Delphi round (coronary heart disease, 245 
reproductive hormonal profile, long-term offspring metabolic and development outcomes, 246 
and suicide attempts). Of the five additional outcomes added to the 2nd Delphi round, two 247 
were considered to be important towards the core outcomes set (skin disorders and treatment 248 
satisfaction).  249 
 250 
Consultation meeting 251 
Thirteen stakeholders participated in the final consultation meeting: two endocrinologists, 252 
four fertility specialists, two primary care physicians, two gynaecologists, and three lay 253 
consumers. The meeting panel acknowledged that given the varied clinical presentation of 254 
PCOS, it would be impractical to report on all the identified core outcomes in this set in each 255 
individual study. Therefore, the panel advocated dividing the final core set into generic 256 
outcomes (BMI, quality of life, and treatment satisfaction) to be reported in all future studies 257 
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and six specific additional outcome domains (metabolic, reproductive, pregnancy, 258 
psychological, oncological, and long-term outcomes) to be considered for reporting 259 
depending on the study’s design, population characteristics and primary research focus.  260 
 261 
Within the metabolic outcomes domain, the panel noted the high variability in measuring and 262 
reporting on waist/hip ratio in practice, thus the panel advocated its exclusion from the core 263 
set while keeping waist circumference. The panel felt that waist circumference was more 264 
relevant to studies investigating metabolic and cardiovascular outcomes in women with 265 
PCOS, in contrast to BMI which has correlation in all outcome domains, thus it was kept as a 266 
generic outcome. The panel also advocated the exclusion of metabolic syndrome from the 267 
core set while maintaining the reporting on its contributing components: type 2 diabetes, 268 
hypertension and lipid profile. The panel highlighted that measuring insulin resistance is only 269 
recommended in research settings and noted the difficulty of measuring it in clinical practice. 270 
They advocated the use of clamp studies, where possible, in mechanistic, experimental and 271 
laboratory-based research while substituting with simpler measures, such as oral glucose 272 
challenge test area under the curve, in larger-scale clinical studies.  273 
Obstructive sleep apnoea, snoring, and daytime sleepness where voted as equivocal outcomes 274 
by both groups in the Delphi process. The panel acknowledged the increased prevalence of 275 
obstructive sleep apnoea in women with PCOS and its association with adverse health 276 
outcomes. However, those outcomes were not considered critical enough to be included as 277 
core.  278 
Venous thromboembolic disease was considered a core outcome given its higher incidence in 279 
women with PCOS and the severity of associated morbidity (Okoroh et al., 2015). The panel 280 
acknowledged that other adverse events, such as treatment side effects and allergic reaction 281 
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(Domecq et al., 2013), could be of critical importance for reporting in clinical trials as per the 282 
principals of Good Clinical Practice in clinical research (Guideline, 2002), but none were 283 
specifically highlighted as core in this set.  284 
 285 
In the reproductive outcomes domain, the panel considered subfertility to be a 286 
complementary outcome to live birth and viable pregnancy with high variation in its 287 
reporting and follow up periods. Therefore, subfertility was excluded in favour of keeping 288 
viable pregnancy, pregnancy loss and live birth as core. The panel deemed heavy menstrual 289 
bleeding to be less relevant to women with PCOS in contrast to menstrual regularity, thus the 290 
former was voted out of the final core set. Elements of hyperandrogenism (biochemical and 291 
clinical e.g hirsutism) were considered equally important and investigators are encouraged to 292 
report on both where possible using standardised tools, as highlighted by the 2018 evidence-293 
based guidelines (Teede et al., 2018).  294 
All outcomes adopted from the Core Outcome Measures for Infertility Trials (COMMIT) 295 
core set (Duffy and Farquhar, 2017) were voted as core in our Delphi process. To avoid 296 
confusion, the panel considered all outcomes in the COMMIT set to be relevant to PCOS 297 
fertility studies, thus investigators evaluating reproductive outcomes in women with PCOS 298 
are encouraged to consider both sets for reporting on core reproductive outcomes as a 299 
minimum. 300 
In the pregnancy outcomes domain, the panel acknowledged the higher risk of both pre-301 
eclampsia and pregnancy-induced hypertension in women with PCOS and advocated the 302 
reporting on the full spectrum of hypertensive disease in pregnancy as per established 303 
definitions (The National Institute for Health and Care Excellence, 2019). The lay consumers 304 
on the panel expressed the importance of breastfeeding in mothers with PCOS to improve 305 
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both maternal and offspring outcomes. However, the panel consensus was not to include 306 
breastfeeding as a core outcome, as the relationship to PCOS was unclear, but rather to 307 
highlight its importance as an outcome favoured by lay consumers.  308 
Both the health professionals and the lay consumers advocated the inclusion of offspring 309 
long-term metabolic and developmental outcomes in the core set. The panel acknowledged 310 
the evidence suggesting a link between fetal in utero exposure in mothers with PCOS and 311 
future adverse offspring metabolic and developmental outcomes such as obesity, metabolic 312 
syndrome, insulin resistance, and autism (Bell et al., 2018; Kosidou et al., 2016; Sir-313 
Petermann et al., 2009; Wilde et al., 2018). However, the panel was also unable to 314 
recommend a set follow up period for the offspring of mothers with PCOS, nor suggest 315 
standardised measurement tools for reporting in this group. Given the difficulties associated 316 
with reporting on these outcomes, the panel acknowledged they would only be suitable for 317 
specific types of clinical studies with planned long-term follow-up. Further work is required 318 
to evaluate the prevalence and association of those metabolic and developmental outcomes in 319 
the offspring of mothers with PCOS to then prioritise core outcomes of importance for future 320 
studies.  321 
 322 
Two oncology related outcomes were prioritised by the Delphi process: endometrial 323 
hyperplasia and endometrial cancer. Given the high association between both outcomes and 324 
the common pathophysiology, the panel advocated combining them into one core outcome 325 
reporting on abnormal endometrial proliferation in women with PCOS.  326 
 327 
Four psychological outcomes were prioritised by the Delphi process, all highly emphasised 328 
by lay consumers (anxiety, depression, eating disorders, and suicidal attempts). The panel 329 
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acknowledged the lack of a standardised definition and measurement tools to report on 330 
suicidal attempts in the context of randomised trials and therefore excluded it from the final 331 
core set, keeping the three remaining psychological outcomes.  332 
 333 
Discussion 334 
Summary of findings 335 
In this study, we report on the development of the first core outcome set for harmonising 336 
PCOS research worldwide, to our knowledge. The final core set included 33 outcomes 337 
categorised in seven clinical practice domains (AUTHOR: please would you recheck: six or 338 
seven domains?). We leveraged extensive evidence syntheses on PCOS (40 systematic 339 
reviews) from the International PCOS guideline to capture the full range of outcomes and 340 
engaged a wide multidisciplinary stakeholder panel from high-, middle-, and low-income 341 
countries in a Delphi and workshop process. Lay consumer input had a pivotal role in the 342 
development of this core set, exemplified by focus on specific outcome domains such as 343 
mental health.  344 
 345 
Strength and limitations 346 
We used a robust methodology to identify outcomes relevant to PCOS research and to reach 347 
consensus among stakeholders. We registered our study prospectively and used predefined 348 
consensus criteria to identify outcomes of core importance. Stakeholders participated 349 
anonymously in the Delphi process to maintain their autonomy and avoid overt influence of 350 
particular individuals or stakeholder groups on the final score (Okoli and Pawlowski, 2004). 351 
We ensured sufficient representation of all relevant stakeholder groups from high-, middle- 352 
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and low-income countries and collaborated with leading professional charities and lay 353 
consumer support groups to expand our pool of participants. We employed a special survey 354 
for lay consumers using lay terminology to promote their effective participation in the Delphi 355 
process. We held a final consultation meeting and engaged a panel of all participating 356 
stakeholder groups promoting an interactive forum to agree on equivocal outcomes, and to 357 
discuss the practical implementation of the final core set. 358 
 359 
Our findings are limited by the 26% attrition rate in the 2nd Delphi round, which could have 360 
influenced the final list of prioritised outcomes. This, however, is not uncommon in Delphi 361 
methodology (Dos Santos et al., 2018; Al Wattar et al., 2017). We were unable to hold focus 362 
groups or structured interviews with lay consumers, which may have limited our 363 
understanding of their choices on key outcomes. Still, we engaged a large number of lay 364 
consumers from many countries and ensured adequate representation in the final consultation 365 
meeting. To ensure feasibility, we combined some outcomes under one label (e.g. lipid 366 
profile); including all individual outcomes in the Delphi process might have changed the final 367 
set.  368 
 369 
Implications for future research 370 
The diverse clinical features of PCOS demand studies of different design and focus to address 371 
the current research need. To aid the implementation of this core set in practice, we divided 372 
outcomes into different outcome domains to cover the varied pathophysiology of PCOS. 373 
Investigators are encouraged to adapt their primary reporting according to the clinical focus 374 
of their study and their established research question, aiming to cover all relevant core 375 
outcomes in this set. For example, studies evaluating fertility treatments in a non-pregnant 376 
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PCOS population might not be able to report on the core outcomes within the oncology 377 
domain, but should aim to report on all generic core outcomes in addition to those in the 378 
reproductive domain, while justifying the lack of reporting on any remaining outcome 379 
domains. We also encourage investigators to consult all additional core sets that might apply 380 
to studies on women with PCOS within the CoRe Outcomes in Women's and Newborn health 381 
(CROWN) and the Core Outcome Measures in Effectiveness Trials (COMET) initiatives’ 382 
databases, given the diverse nature of PCOS. Thus, in the same previous example, 383 
researchers evaluating fertility treatments in women with PCOS are encouraged to report on 384 
the generic and reproductive outcomes in both this HARP (HARmonising research outcomes 385 
for Polycystic ovary syndrome) (AUTHOR: can HARP be defined here?) and the COMMIT 386 
fertility core outcome sets (Duffy and Farquhar, 2017).  387 
 388 
The voice of lay consumers was strong in the development of this core outcome set and led to 389 
a significant change in the convergence of consensus among participating stakeholders. This 390 
was more evident for mental health, offspring, and pregnancy outcomes. Traditionally, those 391 
outcomes have been poorly reported on in the literature (Teede et al., 2018) and we hope that 392 
implementing this core set would help to raise their profile, ultimately increasing research 393 
impact on women’s health and the whole society. A major challenge to adopting all the views 394 
of lay consumers was related to the lack of clear definitions and standardised measurement 395 
tools for some outcomes especially in the case of long-term offspring follow-up.  396 
 397 
We aimed to generate a list of recommended measurement tools to report on the identified 398 
core outcome set following on from the recommendations of the international guideline 399 
(Teede et al., 2018), however, some outcomes such as insulin resistance lacks unanimity. 400 
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Further research work is required to harmonise reporting on these outcomes in PCOS studies 401 
with input from all involved stakeholders including lay consumers. However, several core 402 
outcomes lacked an internationally standardised measurement tool, such as insulin resistance. 403 
We plan to investigate this further to develop, harmonise and standardise relevant missing 404 
measurement tools to facilitate the implementation of this core set.  405 
 406 
Conclusion  407 
Researchers are encouraged to adopt this core set of 33 outcomes in future studies on women 408 
with PCOS to standardise reporting and enable impactful evidence synthesis. 409 
 410 
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